BR112016013976A2 - método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método - Google Patents

método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método

Info

Publication number
BR112016013976A2
BR112016013976A2 BR112016013976A BR112016013976A BR112016013976A2 BR 112016013976 A2 BR112016013976 A2 BR 112016013976A2 BR 112016013976 A BR112016013976 A BR 112016013976A BR 112016013976 A BR112016013976 A BR 112016013976A BR 112016013976 A2 BR112016013976 A2 BR 112016013976A2
Authority
BR
Brazil
Prior art keywords
cancer
colorectal
affected
individual
stage
Prior art date
Application number
BR112016013976A
Other languages
English (en)
Inventor
Celesti Giuseppe
Laghi Luigi
Original Assignee
Humanitas Mirasole Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humanitas Mirasole Spa filed Critical Humanitas Mirasole Spa
Publication of BR112016013976A2 publication Critical patent/BR112016013976A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

the present invention concerns a method for determining if a subject is affected by a colorectal or pancreatic cancer or for determining the stage and/or the progression of a colorectal cancer. by measuring the presence of a panel of mrnas encoding for transcription factors/genes involved in epithelial to mesenchymal transition in a blood sample, wherein different mrna levels of a set of genes comprising twist1, slug, zeb2, zeb1 and cdh1, are indicative of colorectal cancer or pancreatic cancer diagnosis, and/or of colorectal cancer stage at diagnosis, and/or of crc metastatic progression after surgery. the invention concerns also the use of kits to work the method.
BR112016013976A 2013-12-16 2014-12-16 método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método BR112016013976A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13197367.9A EP2883962B1 (en) 2013-12-16 2013-12-16 High levels of EMT-TFs for the diagnosis of cancer, in particular of colorectal (CRC) and pancreatic (PC) cancer
PCT/EP2014/078095 WO2015091575A2 (en) 2013-12-16 2014-12-16 Different levels in blood cell samples of emt-markers for the diagnosis of cancer, in particular of colorectal (crc) and pancreatic (pc) cancer

Publications (1)

Publication Number Publication Date
BR112016013976A2 true BR112016013976A2 (pt) 2018-01-09

Family

ID=49765386

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016013976A BR112016013976A2 (pt) 2013-12-16 2014-12-16 método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método

Country Status (8)

Country Link
US (1) US10907210B2 (pt)
EP (2) EP2883962B1 (pt)
CN (1) CN105899677B (pt)
BR (1) BR112016013976A2 (pt)
ES (2) ES2651522T3 (pt)
IL (1) IL245766B (pt)
PL (1) PL3083988T3 (pt)
WO (1) WO2015091575A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3286565A1 (en) * 2015-04-21 2018-02-28 Genentech, Inc. Compositions and methods for prostate cancer analysis
CN106636366A (zh) * 2016-11-25 2017-05-10 苏州首度基因科技有限责任公司 预测胃癌转移的基因检测试剂盒及其使用方法
WO2018112122A1 (en) * 2016-12-16 2018-06-21 Drexel University Methods of identifying and treating tumors with sigma1 inhibitors
WO2018184966A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Antibodies binding to steap-1
CN107119072B (zh) * 2017-05-08 2020-10-27 安徽医科大学 一种过表达zeb2基因质粒及其构建方法和应用
CN107164480B (zh) * 2017-06-01 2018-11-06 南昌大学第二附属医院 Zeb2基因表达变异在胰腺癌化疗预后诊断中的应用
WO2023222927A2 (en) * 2022-05-20 2023-11-23 Novigenix Sa Biomarkers for colorectal neoplasia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2301268B1 (es) 2004-10-25 2009-05-01 Centro De Investigacion Biomolecular Aplicada Salamanca, S.L. Empleo del gen slug, o de sus productos de replicacion, transcripcion o expresion, en la identificacion, diagnostico, prevencion o tratamiento de la diseminacion del cancer y/o desarrollo de metastasis.
CA2662843A1 (en) 2006-09-07 2008-03-13 Universidad De Salamanca Identification of cancer stem cells using genetic markers
WO2012103025A2 (en) * 2011-01-24 2012-08-02 Epic Sciences, Inc. Methods for obtaining single cells and applications of single cell omics
US9896730B2 (en) * 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment

Also Published As

Publication number Publication date
PL3083988T3 (pl) 2020-12-28
CN105899677A (zh) 2016-08-24
IL245766B (en) 2020-01-30
ES2651522T3 (es) 2018-01-26
EP3083988A2 (en) 2016-10-26
WO2015091575A2 (en) 2015-06-25
WO2015091575A3 (en) 2015-08-13
EP3083988B1 (en) 2020-06-10
IL245766A0 (en) 2016-07-31
US10907210B2 (en) 2021-02-02
CN105899677B (zh) 2020-03-17
ES2815526T3 (es) 2021-03-30
EP2883962B1 (en) 2017-09-13
EP2883962A1 (en) 2015-06-17
US20160312296A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
BR112016013976A2 (pt) método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método
MX2017010836A (es) Panel biomarcador para la deteccion de cancer.
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
EP3744859A3 (en) Microrna biomarker for the diagnosis of gastric cancer
WO2018187496A8 (en) PLASMA PROTEIN PROFILING FOR THE EARLY PROGNOSIS OF LUNG CANCER
NZ624816A (en) Ratio based biomarkers and methods of use thereof
MA39776A (fr) Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
IN2013CN01129A (pt)
MX2016006125A (es) Procedimiento, matriz y uso de los mismos.
CL2017001972A1 (es) Biomarcadores para cáncer pancreático
MX2018013621A (es) Metodo, matriz y uso de estos.
MX2019008911A (es) Metodos, matrices y usos de estos.
EP2619587A4 (en) BIOMARKERS FOR RECURRENCE PREDICTION OF COLORECTAL CANCER
EP3495502A3 (en) Biomarkers for premature birth
WO2014187884A3 (en) Mirnas as non-invasive biomarkers for heart failure
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
BR112017011026A2 (pt) métodos analíticos e arranjos para uso nos mesmos
PH12015501778A1 (en) Markers associated with wnt inhibitors
MX2016012278A (es) Deteccion temprana de preeclampsia.
GB201206323D0 (en) Methods and arrays for use in the same

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements